Ariel Investments, an investment management company, released its "Ariel Global Fund" fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Ariel Global Fund delivered solid results in 2025, rising +23.30% for the year and outperforming both the MSCI ACWI and MSCI ACWI Value indices, although it lagged benchmarks in the fourth quarter with a +2.88% return versus +3.29% and +3.66%, respectively, for the indexes. The quarter unfolded against a constructive global backdrop, as moder ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Gets FDA Approval for Hodgkin's Lymphoma Treatment Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company’s combination treatment for adults and adoles ...

In this article, we are going to discuss the 15 large-cap stocks with highest dividends.Large-cap stocks are usually issued by established companies with long track records. These are often well-known names that have been operating for years. Many of them are referred to as “blue chips,” known for producing reliable goods and services while maintaining steady growth and consistent dividend payments.These companies often hold strong positions in their industries. Their brands are widely recognized, often by ...

Is BMY a good stock to buy? We came across a bullish thesis on Bristol-Myers Squibb Company on MaxDividends’s Substack by Serhio MaxDividends. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company's share was trading at $59.43 as of  March 26th. BMY’s trailing and forward P/E were 16.61 and 9.20 respectively according to Yahoo Finance. Is BMY a good stock to buy? Jirsak/Shutterstock.com Bristol Myers Squibb (BMY) is a leading global biopharmaceutical company with a div ...

Jim Cramer reviewed Bristol-Myers Squibb Company (NYSE:BMY) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Cramer explained why the Charitable Trust owns the stock, as he remarked: Finally, there’s Bristol-Myers. Okay, this is a stock I like so much that we own it for the Charitable Trust. It was on a massive run from November through February, but then this month, it’s just, it stalled. Still, Bristol-Myers is up a quiet 28% since the end of October. In re ...

Key Takeaways Merck will acquire Terns Pharma for $6.7B, adding leukemia candidate TERN-701 to its pipeline.MRK's recent deals span oncology, immunology, and antivirals to reduce heavy Keytruda reliance.Keytruda drives over half of MRK pharma sales, with LOE in 2028 pushing the need for new growth drivers.Merck (MRK) has been actively pursuing mergers and acquisitions (M&A) to strengthen its pipeline and sustain long-term growth, particularly in oncology and immunology. The company’s recent deals reflect a ...

Key Takeaways Bristol Myers expands Opdivo into new cHL settings, broadening reach across treatment lines.Label expansions and pipeline progress aim to offset generic pressure on legacy drugs like Revlimid.Oncology competition intensifies as Merck and Pfizer advance bispecifics and diversified cancer pipelines.Bristol Myers Squibb (BMY) recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo.The FDA approved Opdivo in combination wi ...

Even the most dedicated income investors often avoid healthcare titles, especially those in the high-capital-expenditures pharmaceutical sector. As ever, though, we can find exceptions. Here's a brief look at two that buck the sector's general trend by not only paying dividends regularly, but also raising them on a consistent basis. Say hello to AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Will AI create the world's first trillionaire? Our team just released a report on the one little-known ...

A big theme for investors in 2026 has been to buy dividend stocks. They can make for valuable investments for not only the recurring income they can generate but also their stability, as they are often fairly safe investments to hang on to. Companies that pay dividends normally have strong financials that enable them to make regular payments -- but that doesn't make them guarantees. Bristol Myers Squibb (NYSE: BMY) is a top healthcare company that pays a great dividend. It currently yields 4.4%, which is f ...

Key Takeaways IBRX is expanding Anktiva beyond NMIBC into broader oncology indications to drive growth.Studies include bladder cancer, NSCLC, pancreatic and other tumors using combo therapies.Strong competition from Merck, Bristol Myers and Roche may challenge market penetration.ImmunityBio’s (IBRX) growth narrative is increasingly tied to the expansion potential of its sole marketed drug, Anktiva, beyond its initial approval in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). While the current ...